Find all the latest information in myeloproliferative neoplasms, arranged by types, translocations, and mutations. Listed below are recently updated categories.
Promising preclinical data on combined JAK, PIM, and CDK4/6 inhibition in MPN
Ruxolitinib, a selective inhibitor of Janus kinase 1/2 (JAK1/2), has proven to be beneficial to patients with...
Investigating the familial occurrence of systemic and cutaneous mastocytosis in adults: A retrospective cohort study
Mastocytosis occurs when too many mast cells accumulate in the skin and/or...
COVID-19 vaccination for hematopoietic stem cell transplant patients
The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...
DRSS: A new disease risk stratification system for hematologic malignancies
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely dependent upon disease type and...
Germline mutations in patients with hematologic malignancies
Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...
Editorial Theme | The management of relapsed/refractory myelofibrosis: Part 4 – investigational combination approaches
The unmet clinical need in treating patients with relapsed or refractory...
Reconstruction of cancer cell lineage history in patients with MPN
The JAK2 V617F mutation is common in the majority of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), where the...
Givinostat in polycythemia vera: Long-term safety and efficacy
Polycythemia vera (PV) is a BCR-ABL1-negative subtype of myeloproliferative neoplasms (MPN), characterized by excessive erythroid...
MPN driver mutations
CALR driver mutations
JAK2 driver mutations
MPL driver mutations
Chronic eosinophilic leukemia
Chronic neutrophilic leukemia
MPN blast phase